مباشر

Endpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3B FierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update FierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown BioPharma DiveInnovation alone is no longer enough in biopharma BioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalability Roche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.com FierceBiotechCould engaging the immune system improve AML outcomes?FierceBiotechWhy AI is changing clinical development FierceBiotechManaging complexity across biopharma modalities eLifeCharacterization and modulation of human insulin degrading enzyme conformational dynamics to control enzyme activity eLifeA macroevolution-inspired approach to reveal novel antibiotic resistance mechanisms eLifeA comprehensive mechanosensory connectome reveals a somatotopically organized neural circuit architecture controlling stimulus-aimed grooming of the <i>Drosophila</i> head

Endpoints News ٢١ يناير ٢٠٢٦

Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s

Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s

المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.